These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22140532)

  • 41. ERG oncogene modulates prostaglandin signaling in prostate cancer cells.
    Mohamed AA; Tan SH; Sun C; Shaheduzzaman S; Hu Y; Petrovics G; Chen Y; Sesterhenn IA; Li H; Sreenath T; McLeod DG; Dobi A; Srivastava S
    Cancer Biol Ther; 2011 Feb; 11(4):410-7. PubMed ID: 21178489
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Delineation of TMPRSS2-ERG splice variants in prostate cancer.
    Hu Y; Dobi A; Sreenath T; Cook C; Tadase AY; Ravindranath L; Cullen J; Furusato B; Chen Y; Thangapazham RL; Mohamed A; Sun C; Sesterhenn IA; McLeod DG; Petrovics G; Srivastava S
    Clin Cancer Res; 2008 Aug; 14(15):4719-25. PubMed ID: 18676740
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells.
    Wang L; Li Y; Yang X; Yuan H; Li X; Qi M; Chang YW; Wang C; Fu W; Yang M; Zhang J; Han B
    Prostate; 2014 May; 74(6):647-58. PubMed ID: 24435928
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.
    Kunderfranco P; Mello-Grand M; Cangemi R; Pellini S; Mensah A; Albertini V; Malek A; Chiorino G; Catapano CV; Carbone GM
    PLoS One; 2010 May; 5(5):e10547. PubMed ID: 20479932
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].
    Guo XQ; Gui YT; Cai ZM
    Yi Chuan; 2011 Feb; 33(2):117-22. PubMed ID: 21377967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.
    Tomlins SA; Palanisamy N; Siddiqui J; Chinnaiyan AM; Kunju LP
    Arch Pathol Lab Med; 2012 Aug; 136(8):935-46. PubMed ID: 22849743
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nuclear receptor ERRα and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer.
    Xu Z; Wang Y; Xiao ZG; Zou C; Zhang X; Wang Z; Wu D; Yu S; Chan FL
    Oncogene; 2018 Nov; 37(48):6259-6274. PubMed ID: 30042415
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Truncated ERG proteins affect the aggressiveness of prostate cancer.
    Wu F; Ding S; Lu J
    Med Hypotheses; 2013 Apr; 80(4):490-3. PubMed ID: 23357671
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
    Attard G; Swennenhuis JF; Olmos D; Reid AH; Vickers E; A'Hern R; Levink R; Coumans F; Moreira J; Riisnaes R; Oommen NB; Hawche G; Jameson C; Thompson E; Sipkema R; Carden CP; Parker C; Dearnaley D; Kaye SB; Cooper CS; Molina A; Cox ME; Terstappen LW; de Bono JS
    Cancer Res; 2009 Apr; 69(7):2912-8. PubMed ID: 19339269
    [TBL] [Abstract][Full Text] [Related]  

  • 50. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transcriptional network involving ERG and AR orchestrates Distal-less homeobox-1 mediated prostate cancer progression.
    Goel S; Bhatia V; Kundu S; Biswas T; Carskadon S; Gupta N; Asim M; Morrissey C; Palanisamy N; Ateeq B
    Nat Commun; 2021 Sep; 12(1):5325. PubMed ID: 34493733
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
    Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
    Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
    Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.
    Kiflemariam S; Mignardi M; Ali MA; Bergh A; Nilsson M; Sjöblom T
    J Pathol; 2014 Oct; 234(2):253-61. PubMed ID: 24931216
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.
    Qu X; Randhawa G; Friedman C; O'Hara-Larrivee S; Kroeger K; Dumpit R; True L; Vakar-Lopez F; Porter C; Vessella R; Nelson P; Fang M
    Cancer Genet; 2013; 206(1-2):1-11. PubMed ID: 23352841
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer.
    Hart M; Wach S; Nolte E; Szczyrba J; Menon R; Taubert H; Hartmann A; Stoehr R; Wieland W; Grässer FA; Wullich B
    FEBS J; 2013 May; 280(9):2105-16. PubMed ID: 23480797
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.
    Butler MS; Roshan-Moniri M; Hsing M; Lau D; Kim A; Yen P; Mroczek M; Nouri M; Lien S; Axerio-Cilies P; Dalal K; Yau C; Ghaidi F; Guo Y; Yamazaki T; Lawn S; Gleave ME; Gregory-Evans CY; McIntosh LP; Cox ME; Rennie PS; Cherkasov A
    Oncotarget; 2017 Jun; 8(26):42438-42454. PubMed ID: 28465491
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phosphorylation of the oncogenic transcription factor ERG in prostate cells dissociates polycomb repressive complex 2, allowing target gene activation.
    Kedage V; Strittmatter BG; Dausinas PB; Hollenhorst PC
    J Biol Chem; 2017 Oct; 292(42):17225-17235. PubMed ID: 28887309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells.
    Wang J; Anderson PD; Luo W; Gius D; Roh M; Abdulkadir SA
    Oncogene; 2012 Apr; 31(14):1794-803. PubMed ID: 21860423
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
    Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA
    Neoplasia; 2006 Jun; 8(6):465-9. PubMed ID: 16820092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.